MiNK Therapeutics Presents New Data Supporting iNKT Cell Therapy for Idiopathic Pulmonary Fibrosis
ByAinvest
Tuesday, Feb 3, 2026 9:31 pm ET1min read
INKT--
MiNK Therapeutics presented new data at Keystone Symposia, showing invariant natural killer T (iNKT) cell depletion in lung tissue of idiopathic pulmonary fibrosis (IPF) patients. This supports the potential of iNKT cell replenishment strategies to restore immune balance and tissue repair in fibrotic lung disease. IPF is a fatal, progressive lung disease with no approved treatments that can reverse fibrosis or restore immune balance, affecting approximately 100,000 patients in the US.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet